17α-estradiol inhibits LAPC-4 prostatic tumor cell proliferation in cell cultures and tumor growth in xenograft animals

Prostate

Volumn 67, Issue 16, 2007, Pages 1719-1728

  Qiao, Yaming ^a   Zhang, Zhi Kai ^a   Cai, Li Qun ^a   Tan, Chen ^a   Imperato McGinley, Julianne L ^a   Zhu, Yuan Shan ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

17 Estradiol; Androgen; Cyclins; Prostate cancer

Indexed keywords

17ALPHA ESTRADIOL; ANDROGEN; ANDROSTANOLONE; CYCLIN A; CYCLIN D1; ESTRADIOL; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; TUMOR CELL; TUMOR GROWTH; XENOGRAFT; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; NEOPLASM; PATHOLOGY; RANDOMIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEREOISOMERISM; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN A; CYCLIN D1; DIHYDROTESTOSTERONE; ESTRADIOL; GENE EXPRESSION; HUMANS; MALE; MICE; MICE, SCID; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEREOISOMERISM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 36849031372     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20656     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Ko YJ, Balk SP. Targeting steroid hormone receptor pathways in the treatment of hormone dependent cancers. Curr Pharm Biotechnol 2004;5:459-470.
3. Risbridger GP, Bianco JJ, Ellem SJ, McPherson SJ. Oestrogens and prostate cancer. Endocr Relat Cancer 2003;10:187-191.
4. Huggins C, Hodges CV. Studies on prostatic cancer I. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-297.
5. Dowling AJ, Tannock IF. Systemic treatment for prostate cancer. Cancer Treat Rev 1998;24:283-301.
6. Bush TL, Barrett-Connor E. Noncontraceptive estrogen use and cardiovascular disease. Epidemiol Rev 1985;7:89-104.
7. Hedlund TE, Johannes WU, Miller GJ. Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro. Prostate 2003;54:68-78.
8. Reddel RR, Sutherland RL. Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro. Cancer Res 1987;47:5323-5329.
9. Shen JC, Klein RD, Wei Q, Guan Y, Contois JH, Wang TT, Chang S, Hursting SD. Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Mol Carcinog 2000;29:92-102.
10. Clark JH, Williams M, Upchurch S, Eriksson H, Helton E, Markaverich BM. Effects of estradiol-17 alpha on nuclear occupancy of the estrogen receptor, stimulation of nuclear type II sites and uterine growth. J Steroid Biochem 1982;16:323-328.
11. Lubahn DB, McCarty KS Jr, McCarty KSSr. Electrophoretic characterization of purified bovine, porcine, murine, rat, and human uterine estrogen receptors. J Biol Chem 1985;260:2515-2526.
12. Li JJ, Li SA. Estrogen-induced tumorigenesis in hamsters: Roles for hormonal and carcinogenic activities. Arch Toxicol 1984;55: 110-118.
13. Li JJ, Li SA. Estrogen carcinogenesis in Syrian hamster tissues: Role of metabolism. Fed Proc 1987;46:1858-1863.
14. Li JJ, Li SA, Oberley TD, Parsons JA. Carcinogenic activities of various steroidal and nonsteroidal estrogens in the hamster kidney: Relation to hormonal activity and cell proliferation. Cancer Res 1995;55:4347-4351.
15. 2+ uptake. Circ Res 1997;81:242-248.
16. Aizu-Yokota E, Ichinoseki K, Sato Y. Microtubule disruption induced by estradiol in estrogen receptor-positive and -negative human breast cancer cell lines. Carcinogenesis 1994;15:1875-1879.
17. Green PS, Bishop J, Simpkins JW. 17 Alpha-estradiol exerts neuroprotective effects on SK-N-SH cells. J Neurosci 1997;17: 511-515.
18. Zhu YS, Cai LQ, Huang Y, Fish J, Wang L, Zhang ZK, Imperato-McGinley J. Receptor isoform and ligand-specific modulation of dihydrotestosterone-induced prostate specific antigen gene expression and prostate tumor cell growth by estrogens. J Androl 2005;26:500-508.
19. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997;3: 402-408.
20. Zhang ZK, Davies KP, Allen J, Zhu L, Pestell RG, Zagzag D, Kalpana GV. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hS NF5. Mol Cell Biol 2002;22:5975-5988.
21. Burfeind P, Chernicky CL, Rininsland F, Ilan J, Ilan J. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 1996;93:7263-7268.
22. Foster JS, Henley DC, Bukovsky A, Seth P, Wimalasena J. Multifaceted regulation of cell cycle progression by estrogen: Regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function. Mol Cell Biol 2001;21:794-810.
23. Onozawa M, Fukuda K, Ohtani M, Akaza H, Sugimura T, Wakabayashi K. Effects of soybean isoflavones on cell growth and apoptosis of the human prostatic cancer cell line LNCaP. Jpn J Clin Oncol 1998;28:360-363.
24. Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 1994;79:573-582.
25. Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ, Arnold A. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev 1999; 20:501-534.
26. Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, Newman D Jr, Farquhar R, Guo Z, Qiu Y, Brodie AM. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: Synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem 2005;48:2972-2984.
27. Yasmeen A, Berdel WE, Serve H, Muller-Tidow C. E- and A-type cyclins as markers for cancer diagnosis and prognosis. Expert Rev Mol Diagn 2003;3:617-633.
28. Amanatullah DF, Reutens AT, Zafonte BT, Fu M, Mani S, Pestell RG. Cell-cycle dysregulation and the molecular mechanisms of prostate cancer. Front Biosci 2000;5:D372-D390.
29. Chen Y, Martinez LA, LaCava M, Coghlan L, Conti CJ. Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1. Oncogene 1998;16:1913-1920.
30. Gregory CW, Johnson RT Jr, Presnell SC, Mohler JL, French FS. Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft. J Androl 2001;22:537-548.
31. Zou JX, Zhong Z, Shi XB, Tepper CG, deVere White RW, Kung HJ, Chen H. ACTR/AIB1/SRC-3 and androgen receptor control prostate cancer cell proliferation and tumor growth through direct control of cell cycle genes. Prostate 2006;66:1474-1486.
32. Chen Y, Robles AI, Martinez LA, Liu F, Gimenez-Conti IB, Conti CJ. Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ 1996;7: 1571-1578.
33. Pravettoni A, Mornati O, Martini PG, Marino M, Colciago A, Celotti F, Motta M, Negri-Cesi P. Estrogen receptor beta (ERbeta) and inhibition of prostate cancer cell proliferation: Studies on the possible mechanism of action in DU145 cells. Mol Cell Endocrinol 2007;263:46-54.
34. Kumar MV, Leo ME, Tindall DJ. Modulation of androgen receptor transcriptional activity by the estrogen receptor. J Androl 1994;15:534-542.
35. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci USA 1998;95:15677-15682.
36. Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, Webster JI, Jensen EV, Nilsson S, Warner M, Gustafsson JA. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci USA 2001;98:6330-6335.
37. Jarred RA, Cancilla B, Prins GS, Thayer KA, Cunha GR, Risbridger GP. Evidence that estrogens directly alter androgen-regulated prostate development. Endocrinology 2000;141: 3471-3477.
38. Li SA, Weroha SJ, Tawfik O, Li JJ. Prevention of solely estrogen-induced mammary tumors in female aci rats by tamoxifen: Evidence for estrogen receptor mediation. J Endocrinol 2002; 175:297-305.
39. Kim ND, Mehta R, Yu W, Neeman I, Livney T, Amichay A, Poirier D, Nicholls P, Kirby A, Jiang W, Mansel R, Ramachandran C, Rabi T, Kaplan B, Lansky E. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat 2002;71: 203-217.
40. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinol 1997;138:863-870.
41. Edwards DP, McGuire WL. 17 alpha-Estradiol is a biologically active estrogen in human breast cancer cells in tissue culture. Endocrinol 1980;107:884-891.
42. Dykens JA, Moos WH, Howell N. Development of 17alpha-estradiol as a neuroprotective therapeutic agent: Rationale and results from a phase I clinical study. Ann N Y Acad Sci 2005;1052: 116-135.